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p53 as a prognostic factor in stage I breast cancer
M Stenmark-Askmahn', 0 Stat', K Olsen2, B Nordenskj6ldl and the South-East Sweden Breast
Cancer Group*
Departments of'Oncology and2Pathology, University Hospital, S-581 85 Linkoping, Sweden.
Sinary Accumulation of the tumour-suppressor protein p53 in breast cancer is associated with several
prognostic factors that indicate an aggressive, rapidly proliferating tumour with an unstable genome. To assess
p53 accumulation in stage I breast cancer and to evaluate the prognostic value of both nuclear and
cytoplasmic p53, 205 patients with node-negative breast cancer and tumour size Ess than or equal to 20 mm
were examined. Immunohistochemistry was performed on frozen sections with the monoclonal antibodies PAb
1801 and DOI. Cllular p53 accumulation, within either the nucleus or the cytoplasm or in both, showed the
same association with different pathobiological variables as nuclear accumulation alone. Eklven per cent of the
tumours showed strong nuclear accumulation and were significantly correlated to age under 50 years, negative
oestrogen receptor status, DNA aneuploidy, high S-phase fraction, high pathological grade and poor prog-
nosis. The distant recurrence rate ratio was 6.2 (P=0.002). It is thus concluded that p53 accumulation is of
prognostic value in early stage breast cancer.
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Breast cancer treatment is primarily based on the traditional
prognostic factors tumour size and presence of lymph node
metastasis. A tumour 20 mm or less in size without lymph
node involvement is associated with a relatively good prog-
nosis, but within 5 years 13% of these will recur and after 20
years this figure rises to 25% (Rosen et al., 1993). In order to
unveil this group of tumours that recur much work has been
done to find reliable prognostic factors that can predict
which patients would benefit from adjuvant therapy (Mc-
Guire et al., 1990). A potential prognostic factor in breast
cancer is the accumulation of the tumour-suppressor protein
p53 (Isola et al., 1992; Thor et al., 1992; AlIred et al., 1993;
Silvestrini et al., 1993; Stenmark-Askmalm et al., 1994). In
case of DNA damage, active p53 regulates the cell cycle,
giving time for repair or, if this fails, induces apoptosis. If
p53 is inactive the growth-controlling function is lost and
damage to the genome is thought to accumulate (Kastan et
al., 1991; Yonish-Rouach et al., 1991; Lane, 1992). Indeed, it
has been shown that human cancers often lose normal p53
activity (Vogelstein, 1990). The normal (wild-type) form of
p53 is usually rapidly metabolised and is therefore not detect-
able by immunohistochemical methods. On the other hand,
inactive or mutated p53 has a longer half-life and accumu-
lates within the cell, thus becoming detectable by immunohis-
tochemistry (Lane and Benchimol, 1990; Yonish-Rouach et
al., 1991). p53 accumulation has been shown to occur in
breast cancer, and it has been associated with several other
prognostic factors indicating an aggressive, rapidly pro-
liferating tumour with an unstable genome. The prevalence
of p53 overexpression in small, node-negative breast cancer
has been reported to be low (Davidoff et al., 1991a, Isola et
al., 1992).
The purpose of the present study was to investigate p53
accumulation in 205 stage I breast cancers and to evaluate
the prognostic value of both nuclear and cytoplasmic p53 as
assessed by immunohistochemistry.
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Materias and method
Patients
The study comprises 205 patients with stage I breast cancer,
according to the International Union Against Cancer staging
system, i.e. tumours smaller or equal to 20 mm, with a
negative lymph node status and without distant metastasis.
The patients were diagnosed during 1985-88 and registered
at the Oncologic Centre, South-East Health Care Region of
Sweden. General mammographic screening was introduced in
the region in 1987. None of the patients received any
preoperative treatment. Patients were treated with breast-
conserving surgery plus 54 Gy breast irradiation or modified
radical mastectomy. Approximately half of the patients
received adjuvant tamoxifen treatment, mainly patients over
the age of 50 with oestrogen (ER) or progesterone (PR)
receptor-positive tumours. Distant recurrence was registered
in 15 patients. The median follow-up period was 5 years.
Immunohistochemistry
The monoclonal antibodies PAbl8O1 and DOI (Oncogene
Science, Manhasset, NY, USA) were used. As a negative
control we used IgG antibodies (Sigma, St Louis, MI, USA).
The tumours were collected from fresh surgical resections
and stored below - 70'C before they were sectioned. The
6iLm frozen sections were air dried and stored at - 20TC.
The sections were then fixed in acetone (4C) for 10 min and
air dried. Endogenous peroxidase activity was quenched
with 0.6% hydrogen peroxide in methanol for 5 min;
thereafter the slides were rinsed with phosphate-buffered
saline (PBS) with 0.1% bovine serum albumin and 0.5%
Tween (PBSA + Tween). To block endogenous avidin-
binding activity the tissue was first treated with avidin
(0.001%) and then, after rinsing with PBSA+Tween, with
biotin (0.01%) (Sigma). The sections were rinsed and placed
in PBSA+Tween for 5min. Normal goat serum (1:5) was
used for 20 min in order to block non-specific immunostain-
ing. The sections were incubated with the primary antibodies
Abl801 (1:50) and DOI (1:300) for 30min, and then with
biotinylated goat antibody (1:500) for 30min. After being
rinsed with PBSA + Tween, they were incubated with
streptABComplex/horseradish peroxidase (1:500) for 30min
(StreptABComplex/HRP Duet, Dako, Glostrup, Denmark).
The sections were rinsed with PBSA + Tween before being
stained with 3,3-diaminobenzidine tetrahydrochloride (DAB)p53 in stap I b cancer
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in PBS with 0.036% hydrogen peroxide for 8 min and then
rinsed with distilled water, counterstained with haematoxylin,
dehydrated in a series of ethanols, cleared in xylene. and
mounted.
DNAflow cvtometrv
DNA flow cytometry was used to determine DNA content
and S-phase fraction. A suspension of isolated nuclei was
prepared as described by Vindel6v et al. (1983) using a
detergent (NP40). trypsin and RNAse. Finally, propidium
iodide was used to stain DNA. The suspensions were
analysed with a Leitz MPV FLOW flow cytophotometer
(Leitz, Wetzlar, Germany) interfaced to a Monroe OC8888
personal computer system (Litton Business, Morris Plains,
NJ, USA). The DNA content of the tumour stemlines were
related to the internal reference cells, which were chicken and
trout erythrocytes. Tumours with a single GI peak in the
near-diploid range were classified as DNA-diploid and others
as DNA-aneuploid. Considering a rectangular S-phase dis-
tribution, the number of cells in S-phase was estimated by
multiplying the number of channels between the GoI and
G, M peaks by the mean number of registrations per channel
in an interval judged as representative for replicating cells.
Hormone receptor analyses
Hormone receptor analysis was performed on specimens col-
lected from fresh surgical resections and stored below
- 70°C. Tumours diagnosed before 1988 were analysed for
ER and PR according to Wrange et al. (1978). The cytosol
was incubated with radioligands and the receptors were
isolated by isoelectric focusing in polyacrylamide gel.
Tumours collected after 1988 were analysed by the Abbott
enzyme immunoassay (EIA) method. The receptor concentra-
tion was expressed as fmol of receptor per Lg of DNA. A
cut-off value of 0.1 fmoljug-' DNA was used for receptor
positivity.
Histological grading
Blocks available at the Department of Pathology in
Link6ping were reviewed by a pathologist. Seventy cases
were histologically typed and graded. Sixty-three cases were
classified as ductal carcinomas and seven as lobular. One
tumour with a predominant in situ component and only a
small invasive component. and one case of medullar car-
cinoma were not graded. The grading was done according to
Bloom and Richardson (1957).
Statistical methods
Chi-square tests for contingency tables were used for testing
the significance of differences in p53 accumulation in relation
to pathobiological variables. Survival curves were computed
with the product limit method presented by Kaplan and
Meier (1958). We used Cox's proportional hazards model
(1972) to estimate and test the relation of p53 accumulation
and other prognostic vanrables to distant recurrence-free sur-
vival. P-values <0.05 were regarded as significant.
Results
p53 accumulation
The sections were independently examined and scored by two
of the authors. Nuclear staining was scored as negative or, if
only a small proportion of the nuclei were stained (1-20%),
as weakly positive, or as strongly positive if over 20% of the
nuclei were clearly stained. Cytoplasmic staining was scored
as negative or positive. The negative controls were all
negative.
The staining patterns for both antibodies were very similar,
with a 95% concordance for the nuclear staining and 93%
for the cytoplasmic staining. The results for 1801 and DO1
were combined and the final score was defined as the highest
score between the two antibodies (Table I). Positivity
irrespective of nuclear or cytoplasmic location was defined as
cellular accumulation.
p53 accumulation andpathobiological ariables
When comparing the degree of p53 accumulation pattern
against the various pathobiological variables. the p53-
negative tumours and tumours with weak positivity were
similar and were thus grouped together. Our further analyses
were therefore based upon the groups of negative or weakly
positive compared with the group of strongly positive. One
of the strongly positive cases is shown in Figure 1. Nuclear
and cellular p53 accumulation showed the same relation to
the other variables. Table II shows how nuclear p53
accumulation was related to different variables. Patient age
under 50, negative ER status. DNA aneuploidy. high S-phase
fraction and poorly differentiated tumours were significantly
correlated with strong nuclear p53 accumulation.
p53 accumulation in relation to distant recurrence-free survival
The estimated distance recurrence-free survival after 5 years
was 73% for those patients with tumours having a high
nuclear p53 accumulation compared with 95% for those
lacking or having little p53 accumulation (Figure 2). The
distribution of patients having distant recurrence is shown in
Table I. According to Cox regression analysis the recurrence
rate ratio was 6.2 (P = 0.002). In the univariate Cox analysis,
both high nuclear and high cellular p53 accumulation were
associated with a poor prognosis, as were negative ER status.
DNA aneuploidy and a high S-phase fraction (Table III).
Cytoplasmic accumulation did not have any additional value
to that of nuclear staining (Figure 3). In the multivariate
analysis, S-phase fraction and DNA ploidy independently
predicted a higher risk of distant recurrence. p53 accumula-
tion added prognostic information to that of S-phase fraction
and DNA ploidy when analysed separately. but not when
Table I Number of cases and intracellular staining pattern of
accumulated p53 for the antibodies PAbI8OI and DOI combined
C- C+
N- 145 (7) 7 152
N+ 16 (1) 14 (1) 30
N++ 4(1) 19(5) 23
165 40 205
N-. N+. N+ +. nuclear negative. weakly positive and strongly
positive respectively. C-. C+. cytoplasmic negative and positive
respectively. Numbers ofpatients having distant recurrence are within
parentheses.
Figure 1 Strong nuclear p53 accumulation in a stage I breast
cancer using PAb1801. Section counterstained with haematoxvlin.
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:.%analysed with both at the same time. When all variables were
included in the multivariate Cox analysis, p53 accumulation
failed to be an independent prognostic factor, as did ER
status and size.
Accumulated p53 in node-negative breast cancer has been
shown to be associated with an aggressive course and a poor
prognosis (Isola et al.. 1992; Allred et al., 1993; Silvestrini et
al., 1993). This study showed that the same can be applied to
small breast cancers (TINO) and that the occurrence of p53
accumulation also is of importance in small tumours.
Accumulation of p53 is more often seen in advanced stages
of breast cancer (Davidoff et al., 1991a), but when seen in
earlier stages the p53 alteration is maintained during breast
cancer progression (Davidoff et al., 1991b; Bartkova et al.,
1993). Alteration of the p53 gene is thus suggested to take
place early in cancer progression, rather than being involved
in the development of metastases.
Cellular p53 accumulation, irrespective of nuclear or
cytoplasmic location, has been shown to add prognostic in-
formation in stage II breast cancer (Stenmark-Askmalm et
al., 1994). In this study no additional prognostic value for
p53 insbge I bha cancer
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cytoplasmic overexpression was found. The role of cytoplas-
mic p53 accumulation is controversial. In this study we did
observe cytoplasmic staining but, when present, usually
accompanied nuclear staining. It is possible that cytoplasmic
accuTiulation reflects a more advanced stage of tumour pro-
gression since an increased prevalence of cytoplasniic
accumulation has been found with increasing tumour stage in
colorectal cancer using the CM1 antibody (Sun et al., 1992;
Bosari et al., 1994). Leakage from the nucleus to the cyto-
plasm due to poor fixation has also been suggested as an
explanation for cytoplasmic staining (Fisher et al., 1994).
1.0- <~- N-/+(n= 182)
0.8- 1
N++ (n= 23)
0.6
0.4-
0.2 -
0
Table II Strong nuclear p53 accumulation for PAbI8O1 and DOI
combined related to different pathological variables
p53N+ +
n n (00 P-value
Age (years)
<50 60 11 (18) 0.038
.50 145 12 (8)
Tumour size (mm)
10 48 4 (8) 0.47
11-20 157 19 (12)
Oestrogen receptor status
Negative 52 14 (27) <0.0001
Positive 153 9 (6)
DNA ploidy type
Diploid 108 3 (3) <0.0001
Aneuploid 97 20 (21)
S-phase fraction (00)
<10 144 7 (5) <0.0001
. 10 61 16 (26)
Histological grade3
Well differentiated 30 1 (3) <0.0001
Moderately differentiated 21 1 (5)
Poorly differentiated 19 9 (47)
'Seventy cases were graded. N+ +. nuclear strongly positive.
2 4 6 8 10
Years
Figue 2 Distant recurrence-free survival related to nuclear p53
immunoreactivity for PAbl80I and DOI combined, regardless of
cytoplasmic accumulation. N-N+. negative or weakly positive:
N + +. strongly positive.
1.0*
0.8
_ 0.6
.0
0 0.4
a.
0.2-
On
N-/+ C+ (n = 21)
N-I+ C- (n= 161)
N++ C- (n = 4)
N++C+(n= 19)
0 2 4 6 8 10
Years
Fire 3 Distant recurrence-free survival related to cytoplasmic
and, or nuclear p53 immunoreactivity for PAbl8O0 and DOI
combined. N- N+, nuclear negative or weakly positive; N + +.
nuclear strongly positive; C+. cytoplasmic positive and C-.
cytoplasmic negative.
Table III Univariate regression analysis (Cox model) ofdistant recurrence related to
strong nuclear p53 accumulation and other prognostic variables
n Rate ratio 95% CI P-value
Nuclear p53 status
Nuclear negative weakly positive 182 1
Nuclear positive 23 6.2 2.2- 17.4 0.002
Tumour size (mm)
<I0 48 1
11-20 157 0.5 0.17-1.5 0.22
Oestrogen receptor status
Negative 52 1
Positive 153 0.35 0.12-0.96 0.048
DNA ploidy type
Diploid 108 1
Aneuploid 97 7.9 1.8-35.1 0.0008
S-phase fraction (%)
<10 144 1
>10 61 6.4 2.03-20.1 0.0006
n n . . .
-0
.1- ih - .
13p53 stage I hrust cancer
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However tumours can exhibit a very heterogeneous staining
pattern, with tumour cells having only nuclear accumulation,
both strong nuclear and cytoplasmic staining and mainly
cytoplasmic staining present within the same tissue section.
Distinct staining of both nucleus and cytoplasm throughout
the section or staining of nuclei only were other staining
patterns observed. Thus, it is unlikely that cytoplasmic stain-
ing is satisfactorily explained by poor fixation only.
In line with the results of others (Isola et al., 1992) strong
accumulation of p53, in contrast to weak accumulation, was
related to other prognostic factors. There are difficulties in
interpreting the staining patterns in immunohistochemistry.
Fisher et al. (1994) have described the importance of optimal
fixation in paraffin-embedded tissue. In another study the
staining intensity did not reflect the proportion of tumour
cells having a gene mutation, but it did show that positive
staining to a great extent corresponded to gene mutations
(Jacquemier et al., 1994).
Results with the two primary antibodies correlated
strongly. If at least one of the two antibodies showed positive
staining, the tumour was regarded as positive. In order to
reduce variation in immunoreactivity when using different
antibodies, and to obtain a higher sensitivity, the staining
results for different antibodies have also been combined in
other studies (Allred et al.. 1993; Jacquemier et al., 1994).
Strong nuclear p53 accumulation was significantly cor-
related to several pathobiological variables, thus indicating
an aggressive, genetically instable and rapidly proliferating
tumour. In fact, poorly differentiated tumours showed strong
overexpression of p53. This is similar to results of other
studies which show that a high malignancy grade is cor-
related with p53 accumulation (Isola et al., 1992; Domagala
et al., 1993; Lipponen et al., 1993). Breast cancer patients
with tumours exhibiting a high S-phase fraction have been
shown to respond to adjuvant cytotoxic treatment (StAl et al.,
1994). It would be of interest to investigate whether tumours
with p53 accumulation, which often exhibit high S-phase
fraction, respond to such treatment. On the other hand, p53
plays an active role in apoptosis and cells lacking functional
p53 protein have been shown to be resistant to both radia-
tion and cytotoxic drugs in in vitro experiments (Lowe et al.,
1993).
Our results show that p53 accumulation can predict
recurrence-free survival. In this study p53 failed to be an
independent prognostic factor when several variables were
included in a multivariate analysis. However, it should be
stated that the number of relapses was low. p53 accumula-
tion added prognostic information to that of S-phase frac-
tion, which in a previous study of stage I breast cancer was
shown to be an independent prognostic factor after adjust-
ment for other variables (StAl et al., 1993). In accord with the
study of Isola et al. (1992), less than half of the highly
proliferative tumours showed strong overexpression of p53
protein. A larger study is needed to further investigate the
role of p53 as an independent prognostic factor in stage I
breast cancer.
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